New Frontier: COVID-19 Crisis Opens Door For Dexcom, Abbott To Bring CGMs Into Hospitals For First Time
Executive Summary
Dexcom and Abbott’s permission by US regulators to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients could open up a new market opportunity post-pandemic.
You may also be interested in...
Exec Chat: Dexcom’s CEO On Meeting New CGM Markets While Scoping Consumer Opportunities
In this first of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO Kevin Sayer discusses Dexcom’s ambitious R&D map to expand into metabolic health and develop innovative new products for diabetes and consumer markets.
Dexcom Works With FDA To Bring CGM To Hospitals After Pandemic
The FDA gave Dexcom and Abbott emergency permission to provide their continuous glucose monitoring systems to hospitals to be used by inpatients and hospital staff. Now the agency has granted Dexcom its breakthrough designation to accelerate the approval of Dexcom’s system for the in-hospital indication.
Exec Chat: Dexcom CEO Kevin Sayer Talks About Access, Growth, Resiliency During Pandemic
Full steam ahead: Dexcom brings its flagship G6 CGM to veterans, creates first registry for in-hospital use and signs collaboration with University of Virginia.